As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Pliant Therapeutics, Inc. The largest reported stake is ADAR1 Capital Management, LLC's, at 8.9%. 15 filings are on record since July 17, 2025 (Schedule 13G, August 14, 2026).
Sell to companies like Pliant Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: ADAR1 Capital Management, LLC · Sole voting: 0 · Shared voting: 5,509,724 · Sole dispositive: 0 · Shared dispositive: 5,509,724 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Citadel Advisors LLC · Sole voting: 0 · Shared voting: 1,418,022 · Sole dispositive: 0 · Shared dispositive: 1,418,022 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Woodline Partners LP · Percent: 3.3% · SCHEDULE 13G/A
- · Holder: Point72 Asset Management, L.P. · Percent: 0.1% · SCHEDULE 13G/A
- · Holder: Kenneth Griffin · Percent: 5% · SCHEDULE 13G
Pliant Therapeutics, Inc. has 15 Schedule 13D or 13G filings on record since 2025-07-17. 1 holder's latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 8.9% | 5,509,724 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| The Vanguard Group | 4.89% | 3,002,348 | SCHEDULE 13G/A, 2025-07-29 | 2025-06-30 |
| 3.5% | 2,143,426 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 | |
| BlackRock, Inc. | 3.4% | 2,104,574 | SCHEDULE 13G/A, 2025-07-17 | 2025-06-30 |
| Woodline Partners LP | 3.3% | 2,026,191 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| 0.9% | 545,228 | SCHEDULE 13G/A, 2026-01-08 | 2025-12-31 | |
| Point72 Asset Management, L.P. | 0.1% | 46,537 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Deep Track Capital, LP | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Pliant Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Pliant Therapeutics, Inc. and the records around it.
Pliant Therapeutics, Inc. elsewhere on the record
- Leadership changes Jul 2026
- Who owns it
Companies that share a holder
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- ADAR1 Capital Management, LLC also filed stake reports on 29 other companies: InMed Pharmaceuticals, Inc. (Oct 2026), Tenax Therapeutics, Inc. (Sep 2026), Adagio Medical Holdings, Inc. (Aug 2026)
- Citadel Advisors LLC also filed stake reports on 58 other companies: Quantinuum Inc. (Oct 2026), REALLOYS INC. (Oct 2026), STARFIGHTERS SPACE, INC. (Oct 2026)
Watch Pliant Therapeutics, Inc.
Get an email when Pliant Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Pliant Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Pliant Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pliant Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 0 | 5,509,724 | 0 | 5,509,724 | SCHEDULE 13G, 2026-08-14 |
| Daniel Schneeberger | 0 | 5,509,724 | 0 | 5,509,724 | SCHEDULE 13G, 2026-08-14 |
| Citadel Advisors LLC | 0 | 1,418,022 | 0 | 1,418,022 | SCHEDULE 13G/A, 2026-08-14 |
| Citadel Advisors Holdings LP | 0 | 1,418,022 | 0 | 1,418,022 | SCHEDULE 13G/A, 2026-08-14 |
| Citadel GP LLC | 0 | 1,418,022 | 0 | 1,418,022 | SCHEDULE 13G/A, 2026-08-14 |
| Citadel Securities LLC | 0 | 673,114 | 0 | 673,114 | SCHEDULE 13G/A, 2026-08-14 |
| Citadel Securities Group LP | 0 | 725,404 | 0 | 725,404 | SCHEDULE 13G/A, 2026-08-14 |
| Citadel Securities GP LLC | 0 | 725,404 | 0 | 725,404 | SCHEDULE 13G/A, 2026-08-14 |
| Kenneth Griffin | 0 | 2,143,426 | 0 | 2,143,426 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Pliant Therapeutics, Inc. by CUSIP 729139105 and gives its principal executive office as 331 Oyster Point Blvd., South San Francisco, CA 94080 (SCHEDULE 13G, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 3.4% | SCHEDULE 13G/A |
| 2025-07-29 | The Vanguard Group | 4.89% | SCHEDULE 13G/A |
| 2025-08-06 | Morgan Stanley | 6.1% | SCHEDULE 13G |
| 2025-08-14 | Deep Track Capital, LP | 6.43% | SCHEDULE 13G/A |
| 2025-09-04 | Point72 Asset Management, L.P. | 6.7% | SCHEDULE 13G |
| 2025-11-14 | Woodline Partners LP | 7.3% | SCHEDULE 13G |
| 2025-11-14 | Deep Track Capital, LP | 0% | SCHEDULE 13G/A |
| 2026-01-08 | Morgan Stanley | 0.9% | SCHEDULE 13G/A |
| 2026-01-22 | Kenneth Griffin | 4.9% | SCHEDULE 13G |
| 2026-01-30 | Kenneth Griffin | 4.9% | SCHEDULE 13G |
| 2026-02-09 | Kenneth Griffin | 5% | SCHEDULE 13G |
| 2026-02-17 | Woodline Partners LP | 3.3% | SCHEDULE 13G/A |
| 2026-02-17 | Point72 Asset Management, L.P. | 0.1% | SCHEDULE 13G/A |
| 2026-08-14 | Kenneth Griffin | 3.5% | SCHEDULE 13G/A |
| 2026-08-14 | ADAR1 Capital Management, LLC | 8.9% | SCHEDULE 13G |
Questions about who owns Pliant Therapeutics, Inc.
Who owns Pliant Therapeutics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Pliant Therapeutics, Inc.: ADAR1 Capital Management, LLC (8.9%, Schedule 13G, filed 2026-08-14).
When did ADAR1 Capital Management, LLC buy into Pliant Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from ADAR1 Capital Management, LLC on this page is the Schedule 13G, filed 2026-08-14, reporting 8.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 15 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Pliant Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 13, 2026 | Leadership change: Robert Iannone appointed | — | Leadership changes | Source |
| April 17, 2026 | Leadership change: I. Pyott departs, Chief Executive Officer, and 2 more | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Pliant Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.